August 30, 2016
On the heels of Pfizer’s failed attempt to acquire Allergan, the US pharmaceuticals giant has been on an M&A shopping spree, most recently announcing tilts for Medivation and AstraZeneca’s antibiotics portfolio in the past week alone. With US healthcare companies sitting on around $300bn of dry powder, our head of M&A Research, Chunshek Chan, looks at what this means for the industry.